Urolithin A Modulation of Haematopoietic Stem Cell Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches fail to adequately enhance the function of haematopoietic stem cells, particularly in increasing engraftment and self-renewal capacity during stem cell transplants, and in treating conditions like anaemia and cancer.
Innovation Solution
The use of urolithin A (UroA) to modulate mitochondrial membrane potential through mitophagy induction in haematopoietic stem and progenitor cells, thereby improving their engraftment, self-renewal, and differentiation capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional culture conditions are used for HSCs, then cells can be maintained in culture, but stem cell function and engraftment capacity are significantly reduced
Solution Approach 1:
The patent changes the chemical composition parameters of the culture medium by adding specific agents (insulin, IGF-1, SCF, TPO, FLT3-L, bFGF, and heparin) at optimized concentrations to maintain HSC functionality and engraftment capacity during culture expansion
2Quantity of substance
If HSCs are expanded in culture to increase cell numbers, then more cells are available for transplant, but the functional quality and long-term blood production capacity are compromised
Solution Approach 1:
The patent applies a pre-transplant culture protocol using specific growth factors and cytokines to prepare HSCs for transplant while preserving their functional capacity, allowing expansion of cell numbers without compromising long-term blood production capability
Solution Approach 2:
The culture medium composition is optimized with specific concentrations of insulin (10^-7 M), IGF-1 (10^-7 M), SCF (100 ng/mL), TPO (100 ng/mL), FLT3-L (100 ng/mL), bFGF (10 ng/mL), and heparin (10 µg/mL) to maintain both cell quantity and functional quality
3Use of energy by moving object
If mitochondrial membrane potential is increased to enhance cellular energy production, then metabolic activity improves, but stem cell function and protection from oxidative damage are reduced
Solution Approach 1:
The patent modifies the metabolic environment by adding insulin and IGF-1 which regulate glucose metabolism and promote anaerobic glycolysis, allowing adequate energy production while maintaining low mitochondrial membrane potential and protecting from oxidative damage
4Reliability
If chemical uncoupling of mitochondrial electron transport chain is applied to lower mitochondrial membrane potential, then stem cell function is maintained, but cellular energy production is reduced
Solution Approach 1:
Instead of using chemical uncouplers that reduce energy production, the patent uses insulin and IGF-1 to shift metabolism toward anaerobic glycolysis, and adds SCF, TPO, and FLT3-L to enhance mitochondrial efficiency, thereby maintaining both energy production and stem cell function with low mitochondrial membrane potential
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
UroA treatment significantly increases the engraftment and long-term blood production in both primary and secondary recipient mice, enhancing the functionality of haematopoietic stem cells and offering therapeutic benefits for conditions such as anaemia, leukopenia, thrombocytopenia, infections, and cancers.
Implementation Method 1
the increased stem cell function may be achieved via modulation of mitochondrial membrane potential through mitophagy induction in cells exposed to UroA
Data Source
AI summary
Use of a urolithin for increasing stem cell function in a population of haematopoietic stem and/or progenitor cells (HSPCs).